These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 9294866)

  • 1. Specificity in structure-based drug design: identification of a novel, selective inhibitor of Pneumocystis carinii dihydrofolate reductase.
    Gschwend DA; Sirawaraporn W; Santi DV; Kuntz ID
    Proteins; 1997 Sep; 29(1):59-67. PubMed ID: 9294866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein flexibility and species specificity in structure-based drug discovery: dihydrofolate reductase as a test system.
    Bowman AL; Lerner MG; Carlson HA
    J Am Chem Soc; 2007 Mar; 129(12):3634-40. PubMed ID: 17335207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
    Piper JR; Johnson CA; Krauth CA; Carter RL; Hosmer CA; Queener SF; Borotz SE; Pfefferkorn ER
    J Med Chem; 1996 Mar; 39(6):1271-80. PubMed ID: 8632434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and computational affinity prediction of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
    Graffner-Nordberg M; Kolmodin K; Aqvist J; Queener SF; Hallberg A
    Eur J Pharm Sci; 2004 May; 22(1):43-54. PubMed ID: 15113582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
    Rosowsky A; Forsch RA; Queener SF
    J Med Chem; 2003 Apr; 46(9):1726-36. PubMed ID: 12699390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
    Rosowsky A; Papoulis AT; Forsch RA; Queener SF
    J Med Chem; 1999 Mar; 42(6):1007-17. PubMed ID: 10090784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
    Gangjee A; Guo X; Queener SF; Cody V; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Apr; 41(8):1263-71. PubMed ID: 9548816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, biological evaluation and computational investigation of novel inhibitors of dihydrofolate reductase of opportunistic pathogens.
    Bag S; Tawari NR; Degani MS; Queener SF
    Bioorg Med Chem; 2010 May; 18(9):3187-97. PubMed ID: 20363634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
    Rosowsky A; Forsch RA; Sibley CH; Inderlied CB; Queener SF
    J Med Chem; 2004 Mar; 47(6):1475-86. PubMed ID: 14998335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
    Robson C; Meek MA; Grunwaldt JD; Lambert PA; Queener SF; Schmidt D; Griffin RJ
    J Med Chem; 1997 Sep; 40(19):3040-8. PubMed ID: 9301666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2,4-Diaminothieno[2,3-d]pyrimidine lipophilic antifolates as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
    Rosowsky A; Papoulis AT; Queener SF
    J Med Chem; 1997 Oct; 40(22):3694-9. PubMed ID: 9357537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CoMFA and CoMSIA analyses of Pneumocystis carinii dihydrofolate reductase, Toxoplasma gondii dihydrofolate reductase, and rat liver dihydrofolate reductase.
    Gangjee A; Lin X
    J Med Chem; 2005 Mar; 48(5):1448-69. PubMed ID: 15743188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
    Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
    Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into DHFR interactions: analysis of Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent 5-(omega-carboxy(alkyloxy) trimethoprim derivatives reveals conformational correlations with activity and novel parallel ring stacking interactions.
    Cody V; Pace J; Chisum K; Rosowsky A
    Proteins; 2006 Dec; 65(4):959-69. PubMed ID: 17019704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
    Rosowsky A; Fu H; Chan DC; Queener SF
    J Med Chem; 2004 May; 47(10):2475-85. PubMed ID: 15115391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure determination of tetrahydroquinazoline antifolates in complex with human and Pneumocystis carinii dihydrofolate reductase: correlations between enzyme selectivity and stereochemistry.
    Cody V; Luft JR; Pangborn W; Gangjee A; Queener SF
    Acta Crystallogr D Biol Crystallogr; 2004 Apr; 60(Pt 4):646-55. PubMed ID: 15039552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim.
    Rosowsky A; Forsch RA; Queener SF
    J Med Chem; 2002 Jan; 45(1):233-41. PubMed ID: 11754594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
    Gangjee A; Vidwans AP; Vasudevan A; Queener SF; Kisliuk RL; Cody V; Li R; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Aug; 41(18):3426-34. PubMed ID: 9719595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
    Gangjee A; Vasudevan A; Queener SF
    J Med Chem; 1997 Sep; 40(19):3032-9. PubMed ID: 9301665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
    Rosowsky A; Papoulis AT; Queener SF
    J Med Chem; 1998 Mar; 41(6):913-8. PubMed ID: 9526565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.